Results 131 to 140 of about 170,256 (261)

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source

Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancer

Cost Effectiveness and Resource Allocation
Background Programmed cell death protein 1 (PD-1) monoclonal antibody, pembrolizumab, is a promising drug for platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (NPC).
Jing Nie, Huina Wu, Qian Wu, Lihui Liu, Ke Tang, Shuo Wang, Jiyong Wu   +6 more
doaj   +1 more source

Immune‐Related Prognostic Gene Identification in Lung Squamous Cell Carcinoma With the Cancer Genome Atlas Mining and Immunohistochemistry Validation

iNew Medicine, EarlyView.
ABSTRACT Objective In the cancer microenvironment, stromal and immune cells hold clinical importance. In lung squamous cell carcinoma (LSCC), the aim of this study was to find immune‐linked gene expression that has prognostic pertinence. Methods From the Cancer Genome Atlas, this study obtained the LSCC gene expression profile.
Weijia Jiang, Jing Xu, Wenwen Ma, Qingjie Zhu, Pawin Pongkorpsakol, Guoping Sun   +5 more
wiley   +1 more source

Pembrolizumab-induced myasthenia gravis: Two patients’ experiences

Checkpoint inhibitors are increasingly used to treat patients with gynecologic malignancies and can cause rare and unusual side effects, also known as immunotoxicities, that are rarely observed in patients receiving traditional immunotherapy.
Robert Higgins, Rachael Piver, Amy Vidalin, Marian Johnson, Leslie Montag, Bunja Rungruang   +5 more
core   +1 more source

Extended Versus Non‐Extended Lymphadenectomy in Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta‐Analysis

Journal of Surgical Oncology, EarlyView.
ABSTRACT Pelvic lymph node dissection is an essential component of radical cystectomy (RC) for bladder cancer (BC), but the optimal extent of lymphadenectomy remains uncertain. We conducted a systematic review and meta‐analysis to compare oncologic and perioperative outcomes between extended and non‐extended lymphadenectomy during RC for BC.
Maria Fernanda Dias Azevedo, Pedro Henrique Souza Brito, Lucas Kallas‐Silva, Bruno Liebl, Beatriz Taveira Constantinou, Bianca Caroline Benedicto, Lucas Paschoalino de Oliveira, Mauricio Dener Cordeiro, William Carlos Nahas, Walid Shabana, Walid Shahrour, Leopoldo Alves Ribeiro‐Filho, Caio Vinicius Suartz   +12 more
wiley   +1 more source

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

Journal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu, Brian Longbottom, Hassan Aziz   +2 more
wiley   +1 more source

Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States

Oncology and Therapy
Introduction First-line treatment of persistent, recurrent, or metastatic (advanced) cervical cancer in patients who have a combined positive score (CPS) ≥ 1 with pembrolizumab + chemotherapy versus standard-of-care chemotherapy provides meaningful ...
Bradley J. Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Shilpi Swami, Dominic Muston, Cumhur Tekin, Steve Keefe, Matthew Monberg   +9 more
doaj   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

JEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto, Eleonora Bongiovanni, Veronica Arese, Michela Camilla Milanesio, Alessia Reali, Massimo Chiarpenello, Gianmauro Numico, Marcella Occelli   +7 more
wiley   +1 more source

Long‐Term Clinical Response After Low‐Dose and Short‐Duration Cemiplimab Therapy in a Patient With Xeroderma Pigmentosum in Nepal

JEADV Clinical Practice, EarlyView.
Capsule Summary Xeroderma pigmentosum (XP) is associated with a high risk of multiple and aggressive cutaneous squamous cell carcinomas (CSCCs). The immune checkpoint inhibitor cemiplimab has been approved in advanced, unresectable, and/or metastatic CSCCs.
Sudip Parajuli, Arnab Panta, Sabina Bhandari, Anne Grange, Florent Grange, Upama Paudel   +5 more
wiley   +1 more source

Pembrolizumab-induced duodenitis mimicking celiac disease

Pembrolizumab is a programmed cell death-1 (PD-1) inhibitor frequently used as primary immunotherapy in many cancers, including melanoma, lung, renal cell, cervical, urothelial, and gastric cancers. Given its immune-checkpoint inhibition and upregulation
Ehrenpreis, Eli D, Gonzalez, Miguel, Asado, Nahren, Lafazanos, Yannis, David, Robin   +4 more
core   +1 more source